New TB drug enters first trial: The good and sad news

The initial human trial of TBA-354 — the first for a tuberculosis drug in six years — is considered a major milestone, but also a sad reminder of the woeful state of TB R&D.

About the author

  • Ma. Eliza Villarino

    Eliza is a veteran journalist focused on covering the most pressing issues and latest innovations in global health, humanitarian aid, sustainability, and development. A member of Mensa, Eliza has earned a master's degree in public affairs and bachelor's degree in political science from the University of the Philippines.